crossover
    2022
    High Quality

    No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: A randomized clinical cross-over trial

    Storgaard JH, Lokken N, Madsen KL

    Published in Journal of Inherited Metabolic Disease

    Methodology

    Randomised double-blind crossover trial of 1000 mg/day resveratrol for 8 weeks in 9 patients with VLCAD or CPT II deficiency

    Key Findings

    Resveratrol did not improve fatty acid oxidation or exercise capacity compared with placebo

    Conclusions

    Mitochondrial-biogenesis agents have not translated into measurable fat oxidation gains in humans

    Limitations

    Nine patients with rare disorders; short duration

    Supplements Studied

    Resveratrol
    Compound

    No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders

    Outcomes Measured

    No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: A randomized clinical cross-over trial

    Study Details

    Year:2022
    Sample Size:9
    Duration:8 weeks
    Quality Score:7/10

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.